作者:Venkatraman Junnotula、Ujjal Sarkar、Charles L. Barnes、Praveen K. Thallapally、Kent S. Gates
DOI:10.1007/s10870-006-9099-z
日期:2006.9
The compound 3-methyl 1,2,4-benzotriazine 1,4-dioxide (1) belongs to a new class of clinically promising, bioreductively-activated antitumor drugs. Reductive metabolism of these triazine di-N-oxides typically produces mixtures of mono-N-oxide analogues. As part of our efforts toward characterization of the in vitro metabolism of 1, we synthesized the 1-oxide (2) and 2-oxide (3) analogues and characterized these compounds using X-ray crystallography. Compounds 2 and 3 (C8H7N3O) crystallized in the monoclinic space group P21/c. Unit cell parameters for 2: a = 9.0466(7), b = 10.5959(8), c = 7.8981(6) Å, β = 98.4940(10), and z = 4. Unit cell parameters for 3: a = 5.7193(4), b = 9.3774(7), c = 13.8427(11) Å, β = 101.6370(10), and z = 4.
化合物3-甲基-1,2,4-苯并三嗪-1,4-二氧化物(1)属于一类临床前景广阔、生物还原活化的抗肿瘤药物。这些三嗪二-N-氧化物通常通过还原代谢产生单-N-氧化物类似物的混合物。为了研究1的体外代谢特征,我们合成了1-氧化物(2)和2-氧化物(3)类似物,并使用X射线晶体学对这些化合物进行了表征。化合物2和3(C8H7N3O)在单斜晶系P21/c空间群中结晶。2的单胞参数为:a=9.0466(7),b=10.5959(8),c=7.8981(6) Å,β=98.4940(10),z=4。3的单胞参数为:a=5.7193(4),b=9.3774(7),c=13.8427(11) Å,β=101.6370(10),z=4。